Biodexa Pharmaceuticals Advances eRapa Phase 3 Trial, FDA Fast Track Designation, and Collaborations for FAP Treatment

Biodexa Pharmaceuticals (BDRX) is advancing a Phase 3 trial for its eRapa formulation to treat familial adenomatous polyposis (FAP). The trial has FDA Fast Track designation and collaborations with CROs LumaBridge and Precision for Medicine. Wall Street is optimistic with an average price target of $200.00 and a consensus "Buy" recommendation. Investors should consider BDRX for potentially transformative gains in the biopharmaceutical sector.